神经分泌生物科学 2025年季度报告

FORM10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromto Commission File Number:0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ofincorporation or organization) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to suchfiling requirements for the past 90 days:Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule12b-2 of the Exchange Act: Large accelerated filer☒Acceleratedfiler☐Non-acceleratedfiler☐Smallerreportingcompany☐Emerginggrowthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was99,705,698as of October21, 2025. NEUROCRINE BIOSCIENCES, INC.TABLE OF CONTENTS Part I. Financial Information Item1. Financial Statements Condensed Consolidated Statements of Income and Comprehensive IncomeCondensed Consolidated Statements of Stockholders' EquityCondensed Consolidated Statements of Cash FlowsNotes to the Condensed Consolidated Financial Statements Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item3. Quantitative and Qualitative Disclosures About Market Risk Part II. Other InformationItem 1. Legal Proceedings Item1A. Risk FactorsItem 5. Other InformationItem6. Exhibits Signatures Item1. Financial Statements NEUROCRINE BIOSCIENCES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(unaudited) NEUROCRINE BIOSCIENCES, INC. NEUROCRINE BIOSCIENCES, INC. NEUROCRINE BIOSCIENCES, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(unaudited) 1.Organization and Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accountingprinciples generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securitiesand Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of theinformation and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensedconsolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fairpresentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanyingunaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly ownedsubsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain reclassificationshave been made to previously reported amounts to conform to the current period presentation. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for theyear ended December31, 2024, included in our Annual Report on Form 10-K (the 2024 Form 10-K) filed with the SEC. The results ofoperations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any otherinterim period or the full year. The condensed consolidated balance sheet as of December31, 2024, has been derived from the auditedfinancial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financialstatements. There were no significant changes to our significant accounting policies as disclosed in the 2024 Form 10-K. Recently Adopted Accounting Pronouncements In No